Seminar 21-11-2014 - Drs. J. Hes
•
0 likes•377 views
Het gebruik van bisfosfonaten is geen weldaad voor de kaak door drs. J. Hes
Report
Share
Report
Share
Download to read offline
Recommended
Seminar 23-03-2016 Dr. L. van Bezooijen
Osteoporose en fracturen bij bewoners met dementie in verpleeghuizen
Iwo glucocorticoids 16.43.40
Door Prof. Dr. Hans Bijlsma wordt ingegaan op de balans tussen effectiviteit en veiligheid bij Glucocorticoїden (GC): leiden GC altijd tot botverlies, of kan het ontstekingsremmend effect sterker zijn dan de direct negatieve effecten op het bot? Zijn de bijwerkingen dosis-afhankelijk? Hoe kijken patiënten tegen bijwerkingen aan? Zijn er nieuwe medicamenten in aantocht met minder bijwerkingen?
Seminar 23-03-2016 mw. Dr. J. van den Bergh
This document discusses treatment failure in a 72-year-old patient with a new fracture after three years of bisphosphonate therapy. It considers whether the patient should continue or switch treatments. It examines definitions of treatment failure including new fractures occurring after a certain duration of therapy, loss of bone mineral density greater than measurement error, and lack of effect on bone turnover markers. Factors like fracture type, treatment duration, compliance, and persistence are relevant to determining when switch to a new treatment may be appropriate.
Osteoporosis 2016 | Relationships between muscle function and bone microarchi...
Osteoporosis 2016 | Relationships between muscle function and bone microarchi...National Osteoporosis Society
Kate Ward's presentation from Osteoporosis 2016: Relationships between muscle function and bone microarchitecture in the Hertfordshire cohort study.
Find out more at: https://nos.org.uk/conferenceOsteoporosis 2016 | What are the properties of the perfect therapy? Prof. Jon...
Osteoporosis 2016 | What are the properties of the perfect therapy? Prof. Jon...National Osteoporosis Society
Prof. Jon Tobias's presentation from Osteoporosis 2016: What are the properties of the perfect therapy?
Find out more at: https://nos.org.uk/conferenceOsteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...National Osteoporosis Society
Dr Steve Cummings presentation from Osteoporosis 2016: Patients receiving bisphosphonates should not take holidays from treatment.
Find out more at: https://nos.org.uk/conference
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic mechanisms and clinical aspects door Prof. dr. S. Ferrari, Geneva, Switzerland. (Engelstalige lezing)IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard Osteoporose en Fractuurpreventie door Dr. L. Maartens, EindhovenRecommended
Seminar 23-03-2016 Dr. L. van Bezooijen
Osteoporose en fracturen bij bewoners met dementie in verpleeghuizen
Iwo glucocorticoids 16.43.40
Door Prof. Dr. Hans Bijlsma wordt ingegaan op de balans tussen effectiviteit en veiligheid bij Glucocorticoїden (GC): leiden GC altijd tot botverlies, of kan het ontstekingsremmend effect sterker zijn dan de direct negatieve effecten op het bot? Zijn de bijwerkingen dosis-afhankelijk? Hoe kijken patiënten tegen bijwerkingen aan? Zijn er nieuwe medicamenten in aantocht met minder bijwerkingen?
Seminar 23-03-2016 mw. Dr. J. van den Bergh
This document discusses treatment failure in a 72-year-old patient with a new fracture after three years of bisphosphonate therapy. It considers whether the patient should continue or switch treatments. It examines definitions of treatment failure including new fractures occurring after a certain duration of therapy, loss of bone mineral density greater than measurement error, and lack of effect on bone turnover markers. Factors like fracture type, treatment duration, compliance, and persistence are relevant to determining when switch to a new treatment may be appropriate.
Osteoporosis 2016 | Relationships between muscle function and bone microarchi...
Osteoporosis 2016 | Relationships between muscle function and bone microarchi...National Osteoporosis Society
Kate Ward's presentation from Osteoporosis 2016: Relationships between muscle function and bone microarchitecture in the Hertfordshire cohort study.
Find out more at: https://nos.org.uk/conferenceOsteoporosis 2016 | What are the properties of the perfect therapy? Prof. Jon...
Osteoporosis 2016 | What are the properties of the perfect therapy? Prof. Jon...National Osteoporosis Society
Prof. Jon Tobias's presentation from Osteoporosis 2016: What are the properties of the perfect therapy?
Find out more at: https://nos.org.uk/conferenceOsteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...National Osteoporosis Society
Dr Steve Cummings presentation from Osteoporosis 2016: Patients receiving bisphosphonates should not take holidays from treatment.
Find out more at: https://nos.org.uk/conference
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic ...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic mechanisms and clinical aspects door Prof. dr. S. Ferrari, Geneva, Switzerland. (Engelstalige lezing)IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard O...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 1 November 2023 - De concept versie van de nieuwe NHG-standaard Osteoporose en Fractuurpreventie door Dr. L. Maartens, EindhovenIWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...Stichting Interdisciplinaire Werkgroep Osteoporose
1) DXA scanning is a reliable and low-radiation method to measure bone mineral density (BMD) at the lumbar spine, hip, and wrist to diagnose osteoporosis.
2) DXA can also detect vertebral fractures (VFA) and measure whole body composition, abdominal fat, and aortic calcification.
3) Interpretation of DXA results requires attention to potential variability between devices, accurate placement of regions of interest, and use of appropriate reference data since BMD can be under or overestimated in certain patients.IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn osteoporose vanuit verpleegkundig perspectief door M.M. van OostwaardIWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. LemsStichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. LemsIWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr. H.C. WillemsIWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. ZillikensIWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)Stichting Interdisciplinaire Werkgroep Osteoporose
This document summarizes osteonecrosis of the jaw (ONJ) associated with antiresorptive agents. It defines ONJ and stages its severity. It discusses the pathogenesis of ONJ and risk factors like underlying disease, treatment duration, and dental procedures. Cancer patients on intravenous bisphosphonates have the highest ONJ risk of 1-8% due to higher drug doses and worse oral/general health. Management involves conservative measures like mouthwashes for early stages and surgery with antibiotics for later stages. Discontinuing antiresorptives may help healing but risks fractures. Teriparatide may help healing in some cases but its use in cancer is uncertain. More research is needed on preventing and treating established ONIWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...Stichting Interdisciplinaire Werkgroep Osteoporose
This systematic review analyzed 895 cases of tumor-induced osteomalacia (TIO) from case reports. TIO is caused by tumors that produce excess fibroblast growth factor 23 (FGF23), which causes hypophosphatemia and osteomalacia. The review found that TIO mostly affects adults aged 40-60 years old, with long diagnostic delays of several years on average. The tumors were located variably but most commonly in the lower limbs or head and neck region. Higher FGF23 levels correlated with larger tumor size. Patients experienced significant bone fragility and fracture rates as high as 60% due to long-term hypophosphatemia. Early tumor detection and removal are important to improve outcomes forIWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumabStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses real-world evidence on denosumab for osteoporosis treatment and fracture prevention. It summarizes several studies, including one that found denosumab reduced fracture risk by 38% compared to placebo in over 25,000 postmenopausal women. Another study showed good long-term persistence with denosumab therapy in over 800 patients. Additional studies observed that zoledronic acid can prevent bone loss following denosumab discontinuation, and bisphosphonate treatment after denosumab provides protection against new vertebral fractures.IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam): Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry StudyIWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den BerghStichting Interdisciplinaire Werkgroep Osteoporose
The document appears to be a presentation on highlights from the ASBMR 2021 conference in San Diego. It discusses several topics that were covered at the conference, including fracture risk assessment, the effects of various osteoporosis treatments on bone mineral density, safety issues like osteonecrosis of the jaw and atypical femoral fractures, the role of vitamin D, and applications of artificial intelligence. The entire document is copyrighted by Prof. Dr. Joop van den Bergh.IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F LemsStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses guidelines for medication to prevent fractures in patients using glucocorticoids. It notes that glucocorticoids significantly increase the risk of vertebral and non-vertebral fractures. While effective anti-osteoporosis drugs are available, many glucocorticoid-treated patients remain untreated. The document reviews new guidelines that simplify treatment criteria to improve implementation and outlines recommendations for when to start bone-sparing medications based on patient factors and glucocorticoid dose and duration. The goal is to optimize fracture prevention in glucocorticoid-treated patients.IWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van OostwaardStichting Interdisciplinaire Werkgroep Osteoporose
Vanuit de verpleegkundigen: Beweging bij verhoogd fractuurrisico.IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den BerghStichting Interdisciplinaire Werkgroep Osteoporose
Implementatie FLS en Post-FLS zorg: inleiding en discussieIWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet GeusensStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses what actions should be taken when a vertebral fracture is discovered incidentally. It notes that vertebral fractures are very common fractures, especially in older individuals, and are often asymptomatic. Having a vertebral fracture significantly increases one's risk for future fractures both in the short and long term. If a vertebral fracture is found incidentally, such as on a CT scan, further investigation is warranted including assessing bone mineral density and checking for underlying bone diseases. Treatment options should also be considered, especially if the individual has low bone density in addition to the vertebral fracture, as this combination confers the highest risk. New automated detection algorithms aim to help identify vertebral fractures on scans to ensure appropriate follow up for individuals.IWO Meeting 13 april 2022 - Prof. Kassim Javaid
This document summarizes a cost-effectiveness model of Fracture Liaison Services (FLS) care in the Netherlands. The model found that FLS care would be highly cost-effective, with a cost of €9,076 per quality-adjusted life year gained. Total 5-year costs with FLS would be only 1.7% higher than current costs but would prevent fractures and improve health outcomes. The model can help decision-makers prioritize secondary fracture prevention and allow local payers and FLS to predict costs and benefits of implementation.
IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. ZillikensStichting Interdisciplinaire Werkgroep Osteoporose
- Wat te doen na stop denosumab, nieuwe ECTS guideline door Prof. Dr. M.C. Zillikens (Rotterdam) IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. ZillikensStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses recommendations from the European Calcified Tissue Society (ECTS) regarding treatment after stopping denosumab therapy. It summarizes findings from ECTS papers in 2017 and 2021 on risks of rebound vertebral fractures when discontinuing denosumab. The ECTS recommends pretreatment or post-treatment with bisphosphonates to prevent bone mineral density loss and fractures after stopping denosumab, especially for those on long-term denosumab therapy of over 2.5 years. New Dutch guidelines advise treating with denosumab for 3 years, then reevaluating fracture risk before extending treatment another 3 years up to a maximum of 10 years, and ensuring adequate bisphosphonate treatment after stopping to preventMore Related Content
More from Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...Stichting Interdisciplinaire Werkgroep Osteoporose
1) DXA scanning is a reliable and low-radiation method to measure bone mineral density (BMD) at the lumbar spine, hip, and wrist to diagnose osteoporosis.
2) DXA can also detect vertebral fractures (VFA) and measure whole body composition, abdominal fat, and aortic calcification.
3) Interpretation of DXA results requires attention to potential variability between devices, accurate placement of regions of interest, and use of appropriate reference data since BMD can be under or overestimated in certain patients.IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn osteoporose vanuit verpleegkundig perspectief door M.M. van OostwaardIWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. LemsStichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. LemsIWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr. H.C. WillemsIWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. ZillikensIWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)Stichting Interdisciplinaire Werkgroep Osteoporose
This document summarizes osteonecrosis of the jaw (ONJ) associated with antiresorptive agents. It defines ONJ and stages its severity. It discusses the pathogenesis of ONJ and risk factors like underlying disease, treatment duration, and dental procedures. Cancer patients on intravenous bisphosphonates have the highest ONJ risk of 1-8% due to higher drug doses and worse oral/general health. Management involves conservative measures like mouthwashes for early stages and surgery with antibiotics for later stages. Discontinuing antiresorptives may help healing but risks fractures. Teriparatide may help healing in some cases but its use in cancer is uncertain. More research is needed on preventing and treating established ONIWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...Stichting Interdisciplinaire Werkgroep Osteoporose
This systematic review analyzed 895 cases of tumor-induced osteomalacia (TIO) from case reports. TIO is caused by tumors that produce excess fibroblast growth factor 23 (FGF23), which causes hypophosphatemia and osteomalacia. The review found that TIO mostly affects adults aged 40-60 years old, with long diagnostic delays of several years on average. The tumors were located variably but most commonly in the lower limbs or head and neck region. Higher FGF23 levels correlated with larger tumor size. Patients experienced significant bone fragility and fracture rates as high as 60% due to long-term hypophosphatemia. Early tumor detection and removal are important to improve outcomes forIWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumabStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses real-world evidence on denosumab for osteoporosis treatment and fracture prevention. It summarizes several studies, including one that found denosumab reduced fracture risk by 38% compared to placebo in over 25,000 postmenopausal women. Another study showed good long-term persistence with denosumab therapy in over 800 patients. Additional studies observed that zoledronic acid can prevent bone loss following denosumab discontinuation, and bisphosphonate treatment after denosumab provides protection against new vertebral fractures.IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...Stichting Interdisciplinaire Werkgroep Osteoporose
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam): Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry StudyIWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den BerghStichting Interdisciplinaire Werkgroep Osteoporose
The document appears to be a presentation on highlights from the ASBMR 2021 conference in San Diego. It discusses several topics that were covered at the conference, including fracture risk assessment, the effects of various osteoporosis treatments on bone mineral density, safety issues like osteonecrosis of the jaw and atypical femoral fractures, the role of vitamin D, and applications of artificial intelligence. The entire document is copyrighted by Prof. Dr. Joop van den Bergh.IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F LemsStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses guidelines for medication to prevent fractures in patients using glucocorticoids. It notes that glucocorticoids significantly increase the risk of vertebral and non-vertebral fractures. While effective anti-osteoporosis drugs are available, many glucocorticoid-treated patients remain untreated. The document reviews new guidelines that simplify treatment criteria to improve implementation and outlines recommendations for when to start bone-sparing medications based on patient factors and glucocorticoid dose and duration. The goal is to optimize fracture prevention in glucocorticoid-treated patients.IWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van OostwaardStichting Interdisciplinaire Werkgroep Osteoporose
Vanuit de verpleegkundigen: Beweging bij verhoogd fractuurrisico.IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den BerghStichting Interdisciplinaire Werkgroep Osteoporose
Implementatie FLS en Post-FLS zorg: inleiding en discussieIWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet GeusensStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses what actions should be taken when a vertebral fracture is discovered incidentally. It notes that vertebral fractures are very common fractures, especially in older individuals, and are often asymptomatic. Having a vertebral fracture significantly increases one's risk for future fractures both in the short and long term. If a vertebral fracture is found incidentally, such as on a CT scan, further investigation is warranted including assessing bone mineral density and checking for underlying bone diseases. Treatment options should also be considered, especially if the individual has low bone density in addition to the vertebral fracture, as this combination confers the highest risk. New automated detection algorithms aim to help identify vertebral fractures on scans to ensure appropriate follow up for individuals.IWO Meeting 13 april 2022 - Prof. Kassim Javaid
This document summarizes a cost-effectiveness model of Fracture Liaison Services (FLS) care in the Netherlands. The model found that FLS care would be highly cost-effective, with a cost of €9,076 per quality-adjusted life year gained. Total 5-year costs with FLS would be only 1.7% higher than current costs but would prevent fractures and improve health outcomes. The model can help decision-makers prioritize secondary fracture prevention and allow local payers and FLS to predict costs and benefits of implementation.
IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. ZillikensStichting Interdisciplinaire Werkgroep Osteoporose
- Wat te doen na stop denosumab, nieuwe ECTS guideline door Prof. Dr. M.C. Zillikens (Rotterdam) IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. ZillikensStichting Interdisciplinaire Werkgroep Osteoporose
This document discusses recommendations from the European Calcified Tissue Society (ECTS) regarding treatment after stopping denosumab therapy. It summarizes findings from ECTS papers in 2017 and 2021 on risks of rebound vertebral fractures when discontinuing denosumab. The ECTS recommends pretreatment or post-treatment with bisphosphonates to prevent bone mineral density loss and fractures after stopping denosumab, especially for those on long-term denosumab therapy of over 2.5 years. New Dutch guidelines advise treating with denosumab for 3 years, then reevaluating fracture risk before extending treatment another 3 years up to a maximum of 10 years, and ensuring adequate bisphosphonate treatment after stopping to preventMore from Stichting Interdisciplinaire Werkgroep Osteoporose (20)
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 1 November 2023 - Pitfalls DXA en VFA door Prof. dr. R. Slart (Gr...
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 - Reflectie op en implementatie van de richtlijn o...
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 - Romosozumab anno 2023 door Prof. Dr. W.F. Lems
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Wanneer zoledronaat na een heupfractuur? door Dr....
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 19 April 2023 - Chronische Hypofosfatemie door Prof. Dr. M.C. Zil...
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - ONJ review van ECTS (osteonecrose van de kaak)
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Tumor-induced osteomalacia: a systematic clini...
IWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - Real world data: denosumab
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam)...
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Joop van den Bergh
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Prof. Dr. Willem F Lems
IWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 17 November 2021 - Marsha van Oostwaard
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Joop van den Bergh
IWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO Meeting 13 april 2022 - Prof. Dr. Piet Geusens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens
IWO bijeenkomst - 14 april - Prof. Dr. M.C. Zillikens